Literature DB >> 33658301

A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy.

Miguel F Sanmamed1,2, Xinxin Nie1, Shruti S Desai3, Franz Villaroel-Espindola3, Kurt A Schalper4,5, Lieping Chen6,7,5, Ti Badri1, Dejian Zhao8, Anthony W Kim9, Lan Ji1, Tianxiang Zhang1, Edward Quinlan1, Xiaoxiao Cheng1, Xue Han1, Matthew D Vesely1,7, Ala F Nassar1, Jingwei Sun1, Yu Zhang1,5, Tae Kon Kim5, Jun Wang1, Ignacio Melero2, Roy S Herbst5.   

Abstract

Specific mechanisms by which tumor-infiltrating lymphocytes (TIL) become dysfunctional remain poorly understood. Here, we employed a two-pronged approach using single-cell mass cytometry and tissue imaging technologies to dissect TILs from 25 patients with resectable and 35 patients with advanced non-small cell lung cancer (NSCLC). We identified a burned-out CD8+ TIL subset (Ebo) that specifically accumulated within the tumor microenvironment (TME) but not in adjacent nontumoral tissues. Ebo showed the highest expression of proliferation and activation markers but produced the lowest amount of IFNγ and were the most apoptotic CD8+ TIL subset. Using a humanized patient-derived tumor xenograft model, we demonstrated that Ebo expansion occurred within the TME in a PD-1/B7-H1 pathway-dependent manner. Ebo abundance in baseline tumor tissues was associated with resistance to anti-PD therapy in patients with NSCLC. Our study identifies a dysfunctional TIL subset, with distinct features from previously described exhausted T cells, and implies strategies to overcome immunotherapy resistance. SIGNIFICANCE: We identified a highly proliferative, overactivated, and apoptotic dysfunctional CD8+ tumor-infiltrating subpopulation that is functionally distinct from previously described exhausted T cells. This population is expanded in lung cancer tissues in a PD-1/B7-H1-dependent manner, and its abundance is associated with resistance to cancer immunotherapy, thus becoming a potential tissue biomarker.This article is highlighted in the In This Issue feature, p. 1601. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2021        PMID: 33658301      PMCID: PMC9421941          DOI: 10.1158/2159-8290.CD-20-0962

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   38.272


  48 in total

1.  Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells.

Authors:  Iñaki Etxeberria; Elixabet Bolaños; Jose I Quetglas; Alena Gros; Alberto Villanueva; Jara Palomero; Alfonso R Sánchez-Paulete; Jose María Piulats; Xavier Matias-Guiu; Irene Olivera; Maria C Ochoa; Sara Labiano; Saray Garasa; Inmaculada Rodriguez; August Vidal; Uxua Mancheño; Sandra Hervás-Stubbs; Arantza Azpilikueta; Itziar Otano; M Angela Aznar; Miguel F Sanmamed; Susana Inogés; Pedro Berraondo; Álvaro Teijeira; Ignacio Melero
Journal:  Cancer Cell       Date:  2019-11-21       Impact factor: 31.743

2.  Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade.

Authors:  Chien-Chun Steven Pai; John T Huang; Xiaoqing Lu; Donald M Simons; Chanhyuk Park; Anthony Chang; Whitney Tamaki; Eric Liu; Kole T Roybal; Jane Seagal; Mingyi Chen; Katsunobu Hagihara; Xiao X Wei; Michel DuPage; Serena S Kwek; David Y Oh; Adil Daud; Katy K Tsai; Clint Wu; Li Zhang; Marcella Fasso; Ravi Sachidanandam; Anitha Jayaprakash; Ingrid Lin; Amy-Jo Casbon; Gillian A Kinsbury; Lawrence Fong
Journal:  Immunity       Date:  2019-02-05       Impact factor: 31.745

3.  Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis.

Authors:  Peter Savas; Balaji Virassamy; Chengzhong Ye; Agus Salim; Christopher P Mintoff; Franco Caramia; Roberto Salgado; David J Byrne; Zhi L Teo; Sathana Dushyanthen; Ann Byrne; Lironne Wein; Stephen J Luen; Catherine Poliness; Sophie S Nightingale; Anita S Skandarajah; David E Gyorki; Chantel M Thornton; Paul A Beavis; Stephen B Fox; Phillip K Darcy; Terence P Speed; Laura K Mackay; Paul J Neeson; Sherene Loi
Journal:  Nat Med       Date:  2018-06-25       Impact factor: 53.440

4.  Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses.

Authors:  Yonit Lavin; Soma Kobayashi; Andrew Leader; El-Ad David Amir; Naama Elefant; Camille Bigenwald; Romain Remark; Robert Sweeney; Christian D Becker; Jacob H Levine; Klaus Meinhof; Andrew Chow; Seunghee Kim-Shulze; Andrea Wolf; Chiara Medaglia; Hanjie Li; Julie A Rytlewski; Ryan O Emerson; Alexander Solovyov; Benjamin D Greenbaum; Catherine Sanders; Marissa Vignali; Mary Beth Beasley; Raja Flores; Sacha Gnjatic; Dana Pe'er; Adeeb Rahman; Ido Amit; Miriam Merad
Journal:  Cell       Date:  2017-05-04       Impact factor: 41.582

Review 5.  Molecular and cellular insights into T cell exhaustion.

Authors:  E John Wherry; Makoto Kurachi
Journal:  Nat Rev Immunol       Date:  2015-08       Impact factor: 53.106

6.  viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia.

Authors:  El-ad David Amir; Kara L Davis; Michelle D Tadmor; Erin F Simonds; Jacob H Levine; Sean C Bendall; Daniel K Shenfeld; Smita Krishnaswamy; Garry P Nolan; Dana Pe'er
Journal:  Nat Biotechnol       Date:  2013-05-19       Impact factor: 54.908

7.  Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates.

Authors:  Yannick Simoni; Etienne Becht; Michael Fehlings; Chiew Yee Loh; Si-Lin Koo; Karen Wei Weng Teng; Joe Poh Sheng Yeong; Rahul Nahar; Tong Zhang; Hassen Kared; Kaibo Duan; Nicholas Ang; Michael Poidinger; Yin Yeng Lee; Anis Larbi; Alexis J Khng; Emile Tan; Cherylin Fu; Ronnie Mathew; Melissa Teo; Wan Teck Lim; Chee Keong Toh; Boon-Hean Ong; Tina Koh; Axel M Hillmer; Angela Takano; Tony Kiat Hon Lim; Eng Huat Tan; Weiwei Zhai; Daniel S W Tan; Iain Beehuat Tan; Evan W Newell
Journal:  Nature       Date:  2018-05-16       Impact factor: 49.962

8.  An intra-tumoral niche maintains and differentiates stem-like CD8 T cells.

Authors:  Caroline S Jansen; Nataliya Prokhnevska; Viraj A Master; Martin G Sanda; Jennifer W Carlisle; Mehmet Asim Bilen; Maria Cardenas; Scott Wilkinson; Ross Lake; Adam G Sowalsky; Rajesh M Valanparambil; William H Hudson; Donald McGuire; Kevin Melnick; Amir I Khan; Kyu Kim; Yun Min Chang; Alice Kim; Christopher P Filson; Mehrdad Alemozaffar; Adeboye O Osunkoya; Patrick Mullane; Carla Ellis; Rama Akondy; Se Jin Im; Alice O Kamphorst; Adriana Reyes; Yuan Liu; Haydn Kissick
Journal:  Nature       Date:  2019-12-11       Impact factor: 49.962

9.  Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model.

Authors:  Henrik Jespersen; Mattias F Lindberg; Marco Donia; Elin M V Söderberg; Rikke Andersen; Ulrich Keller; Lars Ny; Inge Marie Svane; Lisa M Nilsson; Jonas A Nilsson
Journal:  Nat Commun       Date:  2017-09-27       Impact factor: 14.919

10.  Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes.

Authors:  Jingjing Zhu; Céline G Powis de Tenbossche; Stefania Cané; Didier Colau; Nicolas van Baren; Christophe Lurquin; Anne-Marie Schmitt-Verhulst; Peter Liljeström; Catherine Uyttenhove; Benoit J Van den Eynde
Journal:  Nat Commun       Date:  2017-11-10       Impact factor: 14.919

View more
  26 in total

Review 1.  Resilient T-cell responses in patients with advanced cancers.

Authors:  Joanina K Gicobi; Emilia R Dellacecca; Haidong Dong
Journal:  Int J Hematol       Date:  2022-07-21       Impact factor: 2.319

2.  Age-dependent genomic characteristics and their impact on immunotherapy in lung adenocarcinoma.

Authors:  Peng Li; Shuyu Che; Yingxue Qi; Ningning Luo; Qiuju Lin; Xiaofeng Zhu; Yunpeng Xuan; Mengmeng Li; Jinlong Li; Minghui Ge; Tingting Sun; Chuang Qi; Yongjie Wang
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-15       Impact factor: 4.322

3.  PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine.

Authors:  Ramin Sedaghat Herati; David A Knorr; Laura A Vella; Luisa Victoria Silva; Lakshmi Chilukuri; Sokratis A Apostolidis; Alexander C Huang; Alexander Muselman; Sasikanth Manne; Oliva Kuthuru; Ryan P Staupe; Sharon A Adamski; Senthil Kannan; Raj K Kurupati; Hildegund C J Ertl; Jeffrey L Wong; Stylianos Bournazos; Suzanne McGettigan; Lynn M Schuchter; Ritesh R Kotecha; Samuel A Funt; Martin H Voss; Robert J Motzer; Chung-Han Lee; Dean F Bajorin; Tara C Mitchell; Jeffrey V Ravetch; E John Wherry
Journal:  Nat Immunol       Date:  2022-07-28       Impact factor: 31.250

4.  Tumour antigen-induced T cell exhaustion - the archenemy of immune-hot malignancies.

Authors:  Miguel Lopez de Rodas; Kurt A Schalper
Journal:  Nat Rev Clin Oncol       Date:  2021-12       Impact factor: 65.011

Review 5.  Clinical implications of T cell exhaustion for cancer immunotherapy.

Authors:  Andrew Chow; Karlo Perica; Christopher A Klebanoff; Jedd D Wolchok
Journal:  Nat Rev Clin Oncol       Date:  2022-10-10       Impact factor: 65.011

6.  Simultaneous and Spatially-Resolved Analysis of T-Lymphocytes, Macrophages and PD-L1 Immune Checkpoint in Rare Cancers.

Authors:  Karina Cereceda; Nicolas Bravo; Roddy Jorquera; Roxana González-Stegmaier; Franz Villarroel-Espíndola
Journal:  Cancers (Basel)       Date:  2022-06-06       Impact factor: 6.575

7.  Identification of an Autophagy-Related Signature Based on Whole Bone Marrow Sequencing for the Prognosis and Immune Microenvironment Characterization of Multiple Myeloma.

Authors:  Licheng Li; Ting Chen; Jishi Wang; Mengxing Li; Qinshan Li
Journal:  J Immunol Res       Date:  2022-05-29       Impact factor: 4.493

Review 8.  The theory of tumor ecosystem.

Authors:  Xueman Chen; Erwei Song
Journal:  Cancer Commun (Lond)       Date:  2022-06-01

Review 9.  Breaking the Immune Complexity of the Tumor Microenvironment Using Single-Cell Technologies.

Authors:  Simone Caligola; Francesco De Sanctis; Stefania Canè; Stefano Ugel
Journal:  Front Genet       Date:  2022-05-16       Impact factor: 4.772

Review 10.  Biomarkers of response to checkpoint inhibitors beyond PD-L1 in lung cancer.

Authors:  Lynette M Sholl
Journal:  Mod Pathol       Date:  2021-10-04       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.